Dostarlimab/Chemo Receives EU Approval for dMMR/MSI-H Endometrial Cancer

News
Article

The European approval for dostarlimab and chemotherapy for dMMR/MSI-H, primary advanced or recurrent endometrial cancer is based on data from part 1 of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.

“Today’s European Commission approval is welcomed news, as I believe it will define a new standard of care for certain patients with advanced or recurrent endometrial cancer in the [European Union],” according toMansoor Raza Mirza, MD.

“Today’s European Commission approval is welcomed news, as I believe it will define a new standard of care for certain patients with advanced or recurrent endometrial cancer in the [European Union],” according toMansoor Raza Mirza, MD.

The European Commission has given authorization to dostarlimab (Jemperli) plus carboplatin/paclitaxel for adult patients with mismatch repair deficient (dMMR)/microsatellite instability­–high (MSI-H), primary advanced or recurrent endometrial cancer, according to a press release from GSK.1 Moreover, the regulatory decision also extends to a conditional approval for single-agent dostarlimab for dMMR/MSI-H, advanced or refractory disease that progressed during or after previous treatment with a platinum-based treatment, which has now transitioned to a full approval.

The approval was based on data from part 1 of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial (NCT03981796), in which investigators reported a statistically significant and clinically meaningful improvement in progression-free survival in the dostarlimab cohort. Additionally, those in the experimental arm achieved a 72% decrease in risk of progression or death vs chemotherapy alone (HR, 0.28; 95% CI, 0.16-0.50).

Moreover, an exploratory overall survival analysis identified a 70% decrease in risk of death in those treated with dostarlimab/chemotherapy compared with chemotherapy alone (HR, 0.30; 95% CI, 0.13-0.70).

“Today’s European Commission approval is welcomed news, as I believe it will define a new standard of care for certain patients with advanced or recurrent endometrial cancer in the [European Union],” principal investigator Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, Denmark, said in the press release. “The results from the RUBY trial, which led to this approval, underscore the practice-changing potential of dostarlimab for these patients.”

Dostarlimab/chemotherapy followed by dostarlimab monotherapy was approved by the FDA as a treatment for those with primary advanced or recurrent, dMMR/MSI-H endometrial cancer.2 This approval was also based on data from the RUBY study.

References

  1. GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer. News release. GSK. December 11, 2023. Accessed December 13, 2023. https://bit.ly/3NiI1mL
  2. Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer. News release. GSK. July 31, 2023. Accessed December 13, 2023. https://shorturl.at/izGL9
Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content